AMENDMENTS TO THE CLAIMS

Claim 1 (currently amended)

A compound selected from the group consisting of all possible isomeric forms and their mixtures, a compound of the formula

Ι

either R₁ is hydrogen or methyl and R₂ is selected from the group consisting of eyclohexyl substituted by an amine, -CH₂-CH₂NHCH₃,

-CH₂CHCH₃NH₂,

-CHCH₃CH₂NH₂, -(CH2)aOH where a is an integer of 1 to 8, -(CH₂)_b B-C_≡N where b is an integer of 1 to 8, -CHCH₃C₆H₅, -(CH₂)-C(CH₃)₂NHCOCF₃, and -CHCH₃(CH₂)dOH where d is an integer of 1 to 8, or R₁ and R₂ together with the nitrogen to which they are attached form a ring of 3, 4 or 5 carbons optionally substituted by an amine

 R_3 is selected from the group consisting of hydrogen, methyl and hydroxyl, R_4 is hydrogen or hydroxyl,

R is selected from the group consisting of alkyl and cycloalkyl of up to 30 carbon atoms, optionally containing at least one heteroatom, at least one heterocycle and alkyl or cyclic acyl of up to 30 carbon atoms optionally containing at least one heteroatom, and at least one heterocycle,

T is selected from the group consisting of hydrogen, methyl, $-CH_2-CONH_2$, $-CH_2-C=N$, and $-(CH_2)_2NH_2$,

Y is selected from the group consisting of hydrogen, hydroxyl, halogen and -OSO₃H or a salt thereof,

. W is hydrogen or OH,

Z is hydrogen or methyl and its non-toxic, pharmaceutically acceptable acid addition salt.

Claim 2 (previously presented)

The compound of claim 1 in which T is hydrogen.

Claim 3 (previously presented)

The compound of claim 1 in which W is hydrogen.

Claim 4 (previously presented)

The compound of claim 1 in which Z is methyl.

Claim 5 (previously presented)

The compound of claim 1 in which Y is hydrogen.

Claim 6 (previously presented)

The compound of claim 1 in which R_3 is methyl.

Claim 7 (previously presented)

The compound of claim 1 in which R_4 is hydroxyl.

Claim 8 (previously presented)

The compound of claim 1 in which R is selected from the group consisting of

<u>....</u>

Claim 9 (previously presented)

The compound of claim 8 in which R is

Claim 10 (previously presented)

The compound of claim 8 in which R is

Claim 11 (previously presented)

The compound of claim 1 in which R_1 is hydrogen.

Claim 12 (cancelled)

Claim 13 (previously presented)

The compound of claim 1 in which R₂ is selected from the group consisting of

$$\begin{array}{ccc} CH_3 & CH_3 \\ & | & | \\ -CH_2\text{-}C(CH_2)_2\text{-}NH_2, \text{-}CH_2\text{-}CH-NH_2, \text{ and } -CH\text{-}CH_2NH_2\text{-} \end{array}$$

Claim 14 (previously presented)

The compound of claim 1 in which R₂ is

$$-CH_2$$
 or $-CH_2$ N H

Claim 15 (currently amended)

The compound of claim 1 is selected from the group consisting of

- 1-[4-[[(1H-benzimidazol-2-yl)-methyl)-amino-N2-[[4"-(pentyloxy) [1,2':4', 1"
- terphenyl]-4-yl]-carbonyl]-L-ornithine]-4-[4-(4-hydroxyphenyl)-L-threonine]5-L-serine-echinocandine B trifluoroacetate (isomer B), and
- trans 1 [4 [(2 aminocyclo hexyl) amino] N2-[[4"(pentyloxy) [1,1':4', 1" terphenyl]
 4 yl carbonyl] L ornithine] 4 [4 hydroxyphenyl) L threonine] 5 L serine
 echinocandine B trifluoroacetate (isomer A).

Claim 16 (cancelled)

Claims 17 and 18 (cancelled)

Claim 19 (previously presented)

An antifungal composition comprising an antifungally effective amount of a compound of claim 15 and an inert pharmaceutical carrier.

Claim 20 (previously presented)

A method of treating fungal infections in warm-blooded animals comprising administering to warm-blooded animals in need thereof an antifungally effective amount of a compound of claim 15.